Life Sciences
Our credentials
We're experienced at working with growth stage companies to hire C-suite, board and executive leaders who have a fundamental impact on business success.
What we offer
Our focus
We work with growth stage businesses, Seed to Series C, AIM or Nasdaq listed, across a range of sectors including biotech, medical devices, instrumentation, digitally led life science and medical technologies.
Our case studies
Start up aiming to develop the best human cell biology research tools to advance medical research and drug discovery.
- CEO
Next generation medical device start up developing innovative Bimodal Electric Tissue Ablation for greater clinical options and improved patient outcomes.
- CEO
Clinically-led teleradiology start up utilising innovative technology to support radiology services with robust and sustainable solutions.
- NED
Genomic data management start up delivering exceptional architectures and data services for clinicians & researchers to optimise healthcare outcomes.
- Head of Talent
Medical device scale up revolutionising breast cancer care with technologies that offer a better standard of care and improved outcomes for patients.
- Head of Clinical Development
Nasdaq listed biotech developing & commercialising innovative therapeutics to improve outcomes for oncology & rare diseases.
- CFO
- VP Business Development
Drug discovery scale up for rare disease treatment using AI to identify novel drug-disease relationships and rapidly scale a drug pipeline.
- CFO
- CSO
Molecular diagnostics start up transforming healthcare by creating instrument free molecular diagnostic technologies.
- Chair
Scale up developing a non-invasive liquid biopsy offering a revolution in how cancer is detected, monitored and treated.
- Clinical Director
Global veterinary telemedicine scale up providing innovative teleradiology and teleconsulting services to an international client base.
- Sales & Marketing Director
Scale up creating sustainable, next-generation transdermal patches for drug delivery that improves quality of life in rare disease treatment.
- Chair
Portfolio-based biopharmaceutical scale up advancing transformative treatments based on breakthrough drug discoveries.
- FD
Pioneering health technology scale up, addressing the global mental health crisis with AI powered, therapist delivered, digital CBT.
- EVP HR
AIM listed global life sciences business designing & engineering genetically modified cells for research & clinical applications.
- HR Director
Scale up developing innovative wound care products that significantly improve the health & wellbeing of patients with chronic wounds.
- QA Director
Surgical augmented intelligence scale up using the latest in cloud GPU computing, computer vision & ML technology to improve Image-Guided Surgery.
- CFO
Scale up pioneering gene synthesis for synthetic biology, with desktop DNA synthesis platform for unprecedented accuracy, scale & speed.
- FD
Privately funded medical technology company which has developed an innovative approach for production of anti-microbial, non-woven fabric.
- CEO
Scale up developing and manufacturing molecularly imprinted polymers (nanoMIPs) for use in a range of immunoassays.
- CCO
- FD
Market leading provider of procurement and materials management software solutions to the high-growth biotechnology sector.
- CTO, Chief People Officer
- Head of Account Management
Organ-on-a-Chip company designing & manufacturing single & multi-organ microphysiological systems.
- CFO
Biomedical institute forming dynamic partnerships to unlock the power of emerging discoveries.
- Executive Director
Biotech start up advancing gene immune therapeutics for infections, cancer and autoimmune diseases.
- Fractional CFO
Series A biotech repurposing and developing existing drugs for novel indications to treat rare diseases.
- Group Reporting Manager
Imperial College spin out transforming diagnostic healthcare through thermal imaging.
- Fractional CMO
- Fractional Head of Regulatory
Venture backed scale up with world-leading technology, enabling cures for liver disease through highly predictive in vitro modelling.
- CFO